Upregulation of microRNA-143 reverses drug resistance in human breast cancer cells via inhibition of cytokine-induced apoptosis inhibitor 1

被引:12
作者
Wang, Jing-Hao [1 ]
Wang, Xiu-Wen [2 ]
Qu, Di [2 ]
Sun, Ji-Wen [2 ]
Guo, Fei-Xiao [2 ]
Lu, Dan [2 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 2, Dept Pharm, Harbin 150086, Heilongjiang, Peoples R China
[2] Harbin Med Univ, Affiliated Hosp 2, Dept Oncol, 246 Xuefu Rd, Harbin 150086, Heilongjiang, Peoples R China
基金
黑龙江省自然科学基金;
关键词
microRNA-143; cytokine-induced apoptosis inhibitor 1; breast cancer; MULTIDRUG-RESISTANCE; CIAPIN1; BIOMARKERS; DIAGNOSIS; MIR-143; MDR-1;
D O I
10.3892/ol.2017.6078
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cytokine-induced apoptosis inhibitor 1 (CIAPIN1), originally termed anamorsin, is an anti-apoptotic molecule that acts as a downstream effector of the receptor tyrosine kinase-Ras signaling pathway. Overexpression of CIAPIN1 contributes to multidrug resistance (MDR) and microRNA (miR)-143 is typically considered a tumor suppressor in breast cancer. The present study aimed to evaluate the therapeutic potential of miR-143 as a treatment for drug-resistant breast cancer via the downregulation of CIAPIN1 in vitro. The expression levels of miR-143 were measured using quantitative polymerase chain reaction and the expression levels of CIAPIN1 were detected via western blot analysis. Bioinformatic analyses was additionally conducted to search for miR-143, which may potentially target CIAPIN1. Luciferase reporter plasmids were created and used to verify direct targeting. In addition, Taxol-induced drug-resistant (TDR) breast cancer cell proliferation was evaluated using the Cell Counting Kit-8 assay in vitro. The present study identified an inverse association between miR-143 and CIAPIN1 protein expression levels in breast cancer MCF-7, MDA-MB-231 and MDA-MB-453 TDR cells. Specific targeting sites for miR-143 in the 3'-untranslated region of the CIAPIN1 gene were identified, which exhibit the ability to regulate CIAPIN1 expression. It was revealed that the repression of CIAPIN1 via miR-143 suppressed the proliferation of breast cancer TDR cells. The findings of the present study verified the role of miR-143 as a tumor suppressor in breast cancer MDR via inhibition of CIAPIN1 translation.
引用
收藏
页码:4695 / 4700
页数:6
相关论文
共 21 条
  • [1] MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer
    Andorfer, Cathy A.
    Necela, Brian M.
    Thompson, E. Aubrey
    Perez, Edith A.
    [J]. TRENDS IN MOLECULAR MEDICINE, 2011, 17 (06) : 313 - 319
  • [2] Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs
    Cascorbi, Ingolf
    [J]. PHARMACOLOGY & THERAPEUTICS, 2006, 112 (02) : 457 - 473
  • [3] Egerton Nancy, 2008, P T, V33, P523
  • [4] Gonzalez-Angulo AM, 2007, ADV EXP MED BIOL, V608, P1
  • [5] Trends in cancer mortality in China: an update
    Guo, P.
    Huang, Z. L.
    Yu, P.
    Li, K.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 (10) : 2755 - 2762
  • [6] CIAPIN1 confers multidrug resistance by upregulating the expression of MDR-1 and MRP-1 in gastric cancer cells
    Hao, Zhiming
    Li, Xiaohua
    Qiao, Taidong
    Du, Rui
    Hong, Liu
    Fan, Daiming
    [J]. CANCER BIOLOGY & THERAPY, 2006, 5 (03) : 261 - 266
  • [7] A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells
    Jiang, Shuai
    Zhang, Ling-Fei
    Zhang, Hong-Wei
    Hu, Song
    Lu, Ming-Hua
    Liang, Sheng
    Li, Biao
    Li, Yong
    Li, Dangsheng
    Wang, En-Duo
    Liu, Mo-Fang
    [J]. EMBO JOURNAL, 2012, 31 (08) : 1985 - 1998
  • [8] Kuo MT, 2007, ADV EXP MED BIOL, V608, P23
  • [9] Li X, 2008, Mol Biol (Mosk), V42, P102
  • [10] A new apoptosis inhibitor, CIAPIN (cytokine-induced apoptosis inhibitor 1), mediates multidrug resistance in leukemia cells by regulating MDR-1, Bcl-2, and Bax
    Li, Xiaohua
    Hong, Liu
    Zhao, Yunping
    Jin, Haifeng
    Fan, Rui
    Du, Rui
    Xia, Lin
    Luo, Guanhong
    Fan, Daiming
    [J]. BIOCHEMISTRY AND CELL BIOLOGY, 2007, 85 (06) : 741 - 750